Instrument Inactif

Communiqués Oncomed Pharmaceuticals Inc

Actions

US68234X1028

Recherche biotechnologique et médicale

Communiqués

15/03/19	OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights	GL
07/03/19	OncoMed Announces Fourth Quarter and Full Year 2018 Financial Results	GL
05/12/18	Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals	GL
09/11/18	OncoMed Announces Early Clinical Data for anti-TIGIT Antibody	GL
22/10/18	OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer	GL
20/10/18	OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer	GL
09/10/18	OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting	GL
24/09/18	OncoMed to Present at the Cantor Global Healthcare Conference	GL
24/09/18	OncoMed Announces Publication of Phase 1a Data of Navicixizumab	GL
20/09/18	OncoMed Provides Update on Navicixizumab Partnership	GL
12/06/18	Oncomed Pharmaceuticals : Doses First Patient in Phase 1b Portion of anti-TIGIT Clinical Trial	PU
08/05/18	OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights	GL
01/05/18	OncoMed Pharmaceuticals to Report First Quarter 2018 Financial Results and Operational Highlights on May 8th, 2018	GL
18/04/18	OncoMed Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting	GL
09/04/18	OncoMed to Present Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting	GL
19/03/18	OncoMed Announces Appointment of John Lewicki, PhD, as President, Chief Executive Officer and a member of the Board of Directors	GL
08/03/18	OncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights	GL
22/02/18	OncoMed Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights on March 8th, 2018	GL
08/01/18	Newman Ferrara LLP : Announces Corporate Governance Investigation of OncoMed Pharmaceuticals Inc. - OMED	BU
04/01/18	OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings has Resigned	GL
04/01/18	OncoMed Provides 2018 Outlook and 2017 Year-End Cash Balance and Announces an Update on the Rosmantuzumab Program	GL
27/11/17	OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings to Resume Chairman Responsibilities	GL
02/11/17	OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights	GL
24/10/17	OncoMed Pharmaceuticals to Report Third Quarter Financial Results and Operational Highlights on November 2nd, 2017	GL
19/09/17	OncoMed Chairman and CEO, Paul Hastings, to Take Medical Leave of Absence	GL